Psyence Biomedical (PBM) Receivables - Accured (2023 - 2026)
Psyence Biomedical's (PBM) quarterly Receivables - Accured came in at $1875.0 in Q1 2026, down 100.0% quarter-over-quarter from $53.7 billion in Q3 2023.
Psyence Biomedical (PBM) Receivables - Accured (2023 - 2026) Analysis & Trends
Psyence Biomedical's Receivables - Accured history runs 2 years deep, the most recent figure standing at $1875.0 for Q1 2026.
- On a quarterly basis, Receivables - Accured changed N/A year-over-year to $1875.0 in Q1 2026; TTM through Mar 2026 was $1875.0, a N/A change from a year earlier, with the FY2026 full-year figure at $1875.0, changed N/A from the prior year.
- Receivables - Accured retreated to $1875.0 in Q1 2026 per PBM's latest filing, from $53.7 billion in the prior quarter.
- Across five years, Receivables - Accured topped out at $53.7 billion in Q3 2023 and bottomed at $1875.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Psyence Biomedical | 1.56 Mn | 1.56 Mn | - | 1,875.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,875.00 |
| Mar 31, 2026 | 1,875.00 |
| Sep 30, 2023 | 53.66 Bn |
| Sep 30, 2023 | 53.66 Bn |